Top Markets
#1 AntFun AntFun +96.36%
#2 Mubarak Mubarak +49.23%
#3 CZ'S Dog CZ'S Dog +34.34%
#4 SODAX SODAX +26.00%
#5 Bitcoin Cash Bitcoin Cash +21.56%
#6 Mina Protocol Mina Protocol +21.52%
#7 Binance-Peg Bitcoin Cash Binance-Peg Bitcoin Cash +21.20%
#8 EXOD EXOD +21.04%
#9 MarsCoin MarsCoin +19.28%
#10 Nillion Nillion +19.23%
Coin of the day
AntFun AntFun
Instellingen
Taal
DUTCH
Valuta
USD
Thema
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
Rang in aandelen #27
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery,... AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Aandeelprijs
$265.95
Marktkapitalisatie
$469.88B
Verandering (1 dag)
0.34%
Verandering (1 jaar)
19.48%
Land
US
Handel AbbVie Inc. (ABBV)

Categorie

Healthcare
Dividendrendementgeschiedenis voor AbbVie Inc. (ABBV)
Het dividendrendement (TTM) van AbbVie Inc. (aandelsymbool: ABBV) per 2024-12-31 is: 3.51%
Gemiddeld dividendrendement over de afgelopen 5 jaar: 3.52%
Dividendrendementgeschiedenis van AbbVie Inc. (ABBV) van 2009 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
2026 (TTM) 2.61% -9.06%
2025 2.87% -18.23%
2024 3.51% -8.83%
2023 3.85% 9.69%
2022 3.51% -9.07%
2021 3.86% -10.65%
2020 4.32% -10.93%
2019 4.85% 23.41%
2018 3.93% 47.74%
2017 2.66% -27.32%
2016 3.66% 7.02%
2015 3.42% 34.12%
2014 2.55% -16.12%
2013 3.04% 0.00%
2012 0.00% 0.00%
2011 0.00% 0.00%
2010 0.00% 0.00%
2009 0.00% 0.00%
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten
Bedrijf Dividendrendement Land
Eli Lilly and Company Eli Lilly and Company
Eli Lilly and Company
LLY.US
0.59%
US
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
JNJ.US
1.98%
US
Roche Holding AG Roche Holding AG
Roche Holding AG
RO.SW
2.69%
CH
Merck & Co., Inc. Merck & Co., Inc.
Merck & Co., Inc.
MRK.US
2.35%
US
Novartis AG Novartis AG
Novartis AG
NOVN.SW
2.80%
CH